Evotec SE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EVO in the last 7 days.
No SEC Form 4 filings for $EVO in the last 30 days.
See all $EVO insider activity →Evotec SE (EVO) began a Phase 1 trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, under a U.S. Department of War program. Developed by its subsidiary Just - Evotec Biologics, the therapy aims to protect against threats like smallpox and mpox. The stock traded at $1.82 on Tuesday, down 2.15%, and was at $1.83 in pre-market trading.
Evotec SE (EVO) and Plectonic Biotech have entered a research collaboration to explore a new immunotherapy approach for solid tumors. The partnership combines Evotec's BiTco platform, which enhances T cell activation, with Plectonic's LOGIBODY® technology, designed for precise tumor recognition. The goal is to improve the precision and potency of T-cell-engaging therapies. Preclinical data will be generated to evaluate the potential of this combined approach.
Evotec SE (EVO) reported Q2 2026 revenue of €143.5m, down from €171.2m, and adjusted EBITDA of -€20.8m. H1 revenue fell to €300.1m from €371.2m, with adjusted EBITDA -€42.7m. It reaffirmed FY2026 guidance: revenue €570-€610m and adjusted EBITDA -€70 to -€105m, citing partnership phasing and slower new ramp-ups.
Recent EVO coverage spans technology, earnings and financial news.
The Phase 1 initiation marks a key milestone that could de‑risk the program and drive near‑term stock volatility.
The partnership could enhance Evotec's immuno‑oncology pipeline and create future revenue streams.
Lower revenue and deeper adjusted EBITDA losses, alongside a materially cut FY2026 revenue and EBITDA outlook, likely pressure sentiment and near-term estimates.
Guidance stability reduces downside risk versus consensus, but the article provides no new upside catalyst beyond reaffirmation.
A strategic collaboration can improve pipeline optionality and validate platform use, though it may be less immediately earnings-relevant than approvals or M&A.
AlphAI scores every news story that mentions EVO with an AI model for sentiment and relevance, and aggregates insider trades from Evotec SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evotec SE (EVO) began a Phase 1 trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, under a U.S. Department of War program. Developed by its subsidiary Just - Evotec Biologics, the therapy aims to protect against threats like smallpox and mpox. The stock traded at $1.82 on Tuesday, down 2.15%, and was at $1.83 in pre-market trading.
2 min readEvotec SE (EVO) and Plectonic Biotech have entered a research collaboration to explore a new immunotherapy approach for solid tumors. The partnership combines Evotec's BiTco platform, which enhances T cell activation, with Plectonic's LOGIBODY® technology, designed for precise tumor recognition. The goal is to improve the precision and potency of T-cell-engaging therapies. Preclinical data will be generated to evaluate the potential of this combined approach.
2 min readEvotec SE (EVO) reported Q2 2026 revenue of €143.5m, down from €171.2m, and adjusted EBITDA of -€20.8m. H1 revenue fell to €300.1m from €371.2m, with adjusted EBITDA -€42.7m. It reaffirmed FY2026 guidance: revenue €570-€610m and adjusted EBITDA -€70 to -€105m, citing partnership phasing and slower new ramp-ups.
6 min readEvotec (NASDAQ: EVO) reaffirmed its FY2026 sales guidance of $667.470 million to $714.310 million, unchanged from prior outlook and near the consensus estimate of $673.750 million. The company also announced an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to discover small-molecule candidates for autoimmune and inflammatory diseases, with milestone payments and no disclosed upfront terms.
4 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readEvotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.
2 min readEvolution AB (publ) said it bought 207,007 of its own shares on 3 Aug 2026, pushing its treasury shareholding above the 5% notification threshold. The company now holds 9,985,643 own shares, or 5.01% of 199,226,613 shares and votes. The buyback is part of a program for up to 19,922,661 shares and EUR 2 billion announced 18 May 2026.
1 min readNavan (NASDAQ: NAVN) said Evotec (NASDAQ: EVO; Frankfurt: EVT) selected Navan to run its global travel and expense program across Germany, the UK, U.S., Italy, and France. Evotec aims to unify tools, reduce manual expense entry, and automate reconciliation from card swipes, according to the companies.
2 min readEvotec said unfavorable FX will cut first-half revenue by about €13 million. It guided Q2 adjusted group EBITDA to about -€20.8 million and -€42.7 million for 1H 2026. Full-year 2026 revenue is now ~€570m-€610m (inc. FX) and adjusted EBITDA -€70m to -€105m. Liquidity rose to €465.6m.
6 min readEvotec SE (NASDAQ: EVO) reported preliminary, unaudited Q2 and first-half 2026 results and updated its full-year outlook. It expects H1 2026 revenue of about €300.1m and adjusted EBITDA of about -€42.7m, with liquidity around €465.6m as of June 30. Full-year 2026 revenue guidance is €570-610m and adjusted EBITDA -€70 to -105m, down from prior €700-780m and €0-40m.
2 min read
